Viemed Healthcare (VMD) Q3 2026 earnings summary

Executive summary

• Record Q3 revenue was $80.673M, up 12.2% YoY and 3.3% sequentially; attributable net income rose 32.0% YoY to $4.638M.

• Growth across respiratory, sleep and women's health marked the first full-year YoY quarterly comparison following the Lehan acquisition.

Financial highlights

• Q3 gross profit was $46.192M vs. $41.345M YoY; operating income was $6.962M vs. $5.642M.

• Attributable net income was $4.638M vs. $3.513M; diluted EPS was $0.11 vs. $0.09.

• Adjusted EBITDA was $17.057M, up 5.8% YoY and 24.4% sequentially; margin was 21.1% vs. 17.6% in Q2.

• 9M revenue was $234.184M vs. $194.099M; attributable net income was $9.984M vs. $9.295M.

Outlook and guidance

• FY2026 revenue guidance increased at the low end to $316M-$320M from $314M-$320M; Adjusted EBITDA guidance narrowed to $64M-$66M from $64M-$68M.

• Net CapEx guidance fell to 8.0%-9.0% of revenue from 8.5%-10.0%, reflecting a greater contribution from less capital-intensive offerings.

• Q4 revenue and Adjusted EBITDA are expected to grow sequentially; guidance excludes potential acquisitions and strategic transactions.

• Maternal health expansion is planned at two additional states per quarter from Q4; new markets require time to ramp.